Skip to main content
. 2020 Mar 11;59(8):967–980. doi: 10.1007/s40262-020-00879-x

Fig. 1.

Fig. 1

Primary direct oral anticoagulant (DOAC) clearance/elimination pathways. Data were extracted from per oral (po; apixaban, edoxaban, and rivaroxaban) and intravenous (iv; betrixaban and dabigatran) mass balance studies [2, 38, 48, 57]. The rivaroxaban pie chart is a modification from Mueck and co-workers [63]. BCRP breast cancer resistance protein, CES carboxylesterase, CYP cytochrome P450, P-gp P-glycoprotein